Abstract
Deferasirox Continues to Reduce Iron Overload in Non-Transfusion-Dependent Thalassemia: A One-Year, Open-Label Extension to a One-Year, Randomized, Double-Blind, Placebo-Controlled Study (THALASSA)
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have